Skip to content
TTM Q1 '26TTM Q4 '25TTM Q3 '25TTM Q2 '25TTM Q1 '25
$86.93M+8.7%$79.95M+13.7%$70.32M+20.9%$58.18M+20.4%$48.33M+23.9%
$39.32M+5.7%$37.21M+8.8%$34.2M+44.8%$23.62M+17.7%$20.06M+28.6%
$47.61M+11.4%$42.74M+18.3%$36.12M+4.5%$34.56M+22.3%$28.27M+20.7%
54.8%+1.3pp53.5%+2.1pp51.4%-8.0pp59.4%+0.9pp58.5%-1.5pp
$8.48M+9.2%$7.77M
$37.1M+3.6%$35.82M+6.3%$33.68M+9.1%$30.86M+15.3%$26.77M+17.6%
$45.57M+4.6%$43.58M+12.3%$38.8M+9.7%$35.37M+15.8%$30.53M+17.4%
-$6.48M-61.0%-$4.03M+10.4%-$4.5M-18.0%
$199K+97.0%$101K+13.5%$89K+493%
-$6.68M-61.9%-$4.13M+9.9%-$4.58M-19.9%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is Eton Pharmaceuticals, Inc.'s revenue?
Eton Pharmaceuticals, Inc. (ETON) generated $86.9M in revenue over the trailing twelve months, up 79.9% year over year.
Is Eton Pharmaceuticals, Inc. profitable?
Eton Pharmaceuticals, Inc. is not currently profitable: it reported a net loss of $4.5M over the trailing twelve months, a -9.5% net margin.
What are Eton Pharmaceuticals, Inc.'s profit margins?
Gross margin is 54.8% and operating margin is -15.1%, with a -9.5% net margin.
What is Eton Pharmaceuticals, Inc.'s earnings per share?
Eton Pharmaceuticals, Inc.'s diluted EPS over the trailing twelve months is $-0.06.
Where does Eton Pharmaceuticals, Inc.'s income statement data come from?
Every line is extracted from Eton Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.